antagonist. These data demonstrate that activation of cannabinoid CB 2 receptors is sufficient to suppress neuronal activity at central levels of processing in the spinal dorsal horn. Our findings are consistent with the ability of AM1241 to normalize nociceptive thresholds and produce antinociception in inflammatory pain states.
INTRODUCTION
Cannabinoids attenuate nociceptive responses in behavioral (Calignano et al. 1998; Martin et al. 1998; Ko and Woods 1999; Farquhar-Smith and Rice 2001; Hanus et al. 1999; Malan et al. 2001) , neurochemical (Tsou et al. 1998; Hohmann et al. 1999b; Nackley et al. 2003a,b) and electrophysiological (Hohmann et al. 1995 (Hohmann et al. ,1998 (Hohmann et al. ,1999a Martin et al. 1996; Drew et al. 2000; Chapman 2001; Harris et al. 2000) studies. Both CB 1 and CB 2 receptor subtypes are implicated in cannabinoid antinociception.
CB 1 is expressed (Matsuda et al. 1990; Munro et al. 1993; Zimmer et al. 1999) in the central nervous system (CNS), whereas CB 2 is expressed mainly in immune cells (Munro et al. 1993; Lynn and Herkenham 1994) and is absent in CNS neurons (Munro et al. 1993; Zimmer et al. 1999; Buckley et al. 2000) . Cannabinoid receptors have been identified on primary afferent fibers (Hohmann and Herkenham 1999b; Bridges et al., 2003) . Recent pharmacological evidence also supports the presence of CB 2 in human and guinea-pig vagus nerve (Patel et al. 2003) . CB 2 has also been identified in microglia (Walter et al. 2003 ) that migrate toward dying neurons during neuroinflammation. In immune tissues, levels of CB 2 mRNA are 10-100 times greater than that of CB 1 (Galiegue et al. 1995) . Ligand binding to Gi/o-coupled CB 2 receptors modulates intracellular signaling cascades through inhibition of adenyl cyclase (Bayewitch et al. 1995) and activation of mitogen-activated protein kinase (Bouaboula et al. 1996) . Unlike CB 1 , CB 2 does not couple to calcium channels (Felder et al. 1995) . Activation of CB 2 inhibits the proliferation of T cells (Patrini et al. 1997 ), B cells (Valk et al. 1997) and natural killer cells (Parolaro et al. 1999) , which act synergistically to produce a robust immune response. Furthermore, CB 2 agonists suppress the expression of proteins elicited by macrophage immunomodulators (Cabral et al. 1989) . Thus, activation of CB 2 modulation of C-fiber responses in WDR neurons 3 CB 2 on immune cells in inflamed tissue may prevent the release of inflammatory mediators (e.g. nerve growth factor, cytokines and ATP) that result in nociceptor sensitization (Mazzari et al. 1996) . CB 2 agonists are antinociceptive in models of acute (Malan et al. 2001 ) and persistent pain (Hanus et al. 1999; Clayton et al. 2002; Nackley et al. 2003a; Ibrahim et al. 2003 ; for review see Hohmann (2002) and Malan et al. (2002) ). Activation of CB 2 also reduces substance P-induced plasma extravasation (Mazzari et al. 1996) and arachidonic acidinduced ear edema (Hanus et al. 1999) . AM1241 (Goutopoulos et al. 2002 ) is a CB 2 -selective agonist that exhibits 340-fold selectivity for CB 2 over CB 1 . AM1241 suppresses thermal nociception in naive rats following systemic and local hind paw injections, while failing to elicit centrally-mediated side-effects such as hypothermia, catalepsy and hypoactivity (Malan et al. 2001) . AM1241 also suppresses carrageenan and capsaicin-evoked thermal and mechanical hyperalgesia and allodynia (Nackley et al. 2003a; Quartilho et al. 2003; Hohmann et al. 2004 ) and carrageenan-evoked Fos protein expression (Nackley et al. 2003a) through a CB 2 -specific mechanism.
In untreated animals, cannabinoids suppress responses evoked in spinal nociceptive neurons (Hohmann et al. 1995 (Hohmann et al. ,1998 (Hohmann et al. ,1999a Strangman and Walker 1999) by attenuating activity of Aδ-and C-fiber primary afferents (Strangman and Walker 1999; Drew et al. 2000; Chapman 2001; Kelly and Chapman 2001) . Repeated activation of C-fibers by electrical stimulation of the cutaneous receptive field leads to a phenomena known as windup, in which the number of neuronal responses progressively increases with subsequent stimulation (Mendell 1966) . Windup is generally attributed to C-fiber afterdischarge-evoked responses of spinal dorsal horn neurons and is involved in the maintenance of inflammatory and neuropathic pain states (Dubner 1986; Gracely et al. 1992) . In the present study, electrophysiological methods were used to directly examine the effects of the CB 2 -selective agonist AM1241 on nociceptive neurons in the lumbar dorsal horn in the absence and presence of inflammation.
Peripheral sensitization of Aδ-and C-fiber terminals occurs at the site of inflammation (Reeh 1994; Hedo et al. 1998) . Central sensitization, observed at the spinal level, is characterized by a decrease in threshold (Neugebauer and Schaible 1990; Simone et al. 1991) , increase in firing rate (Dougherty et al. 1999; Guilbaud et al. 1986 ), enlargement of the receptive field (McMahon and Wall 1984; Ren et al. 1992 ) and recruitment of low threshold Aβ-fibers (Nakatsuka et al. 1999; Neumann et al. 1996) . Opioids and cannabinoids known to suppress inflammatory hyperalgesia also suppress neuronal activity under inflammatory conditions (Drew et al. 2000; Haley et al. 1990; Harris et al. 2000; Hylden et al. 1991; Stanfa et al. 1992) . Recently, local administration of anandamide has been shown to produce a CB 2 -mediated suppression of mechanically-evoked responses in spinal dorsal horn neurons in the carrageenan model of inflammation (Sokal et al. 2003 ).
The present study was conducted to assess the role of CB 2 in modulating the activity of spinal dorsal horn neurons evoked by transcutaneous electrical stimulation in the absence and presence of carrageenan inflammation. We hypothesized that AM1241 would suppress responses evoked in WDR neurons by transcutaneous electrical stimulation of the peripheral receptive field through a CB 2 -specific mechanism. The ability of AM1241 to selectively inhibit the transmission of nociceptive information was evaluated by examining its effects on purely non-nociceptive (low threshold) neurons. Pharmacological specificity was evaluated through the use of competitive antagonists for CB 1 and CB 2 .
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EXPERIMENTAL PROCEDURES
Subjects
Eighty-three adult male Sprague-Dawley rats Harlan, Indianapolis, IN and Charles River Laboratories, Wilmington, MA) were used in these experiments. All procedures were approved by the University of Georgia Animal Care and Use Committee and followed the guidelines for the treatment of animals of the International Association for the Study of Pain (Zimmermann 1983).
Drugs and chemicals
Lambda carrageenan was obtained from Sigma Aldrich (St. Louis, MO). AM1241 was synthesized (by A.M.Z.) in the Departments of Pharmaceutical Sciences and Molecular and Cell Biology at The University of Connecticut. SR141716A, a CB 1 selective antagonist/inverse agonist (Rinaldi-Carmona et al. 1994) , and SR144528, a CB 2 selective antagonist/inverse agonist (Rinaldi-Carmona et al. 1998) , were provided by NIDA.
Carrageenan (3%) was dissolved in saline and administered in a volume of 100 µl. Drugs were dissolved in dimethylsulfoxide (DMSO) for intraplantar administration (50 µl) and in emulphur, ethanol, saline (1:1:3) for intravenous administration (2 ml/kg body weight).
Surgical preparation
Rats were anesthetized with urethane (25%, 1.2 g/kg i.p.). Core body temperature was maintained at 37°C throughout surgical and experimental procedures using a feedbackcontrolled heating pad. A laminectomy was performed for electrophysiological recording as described previously (Hohmann et al. 1995 (Hohmann et al. , 1999 . The tail vein was cannulated for intravenous drug administration. Animals breathed spontaneously and were not artificially ventilated. Respiration was monitored through close observation and ear and extremity color CB 2 modulation of C-fiber responses in WDR neurons 6 was observed to monitor peripheral vascularization (Pertovaara et al. 1998) . Absence of corneal reflexes and paw withdrawal responses to pinch indicated adequate anesthesia (Svendsen et al. 1999) .
Identification of WDR neurons, non-nociceptive neurons and their primary afferent inputs
Wide dynamic range (WDR) neurons were qualitatively identified by responses to mechanical stimulation (innocuous brush and noxious pinch) of the receptive field (Coghill et al. 1993; Hohmann et al. 1999 ). An innocuous brush stimulus was applied using an artist's paint brush. Noxious pinch was applied using teethed hemostats at an intensity deemed noxious by the experimenter. After isolating a single WDR neuron and mapping its receptive field on the plantar surface of the hind paw, each mechanical stimulus was presented for 10 s with a 10 s interstimulus interval. The oscilloscope and data acquisition system were not in view of the experimenter during application of mechanical stimuli (brush, pinch). This procedure served to minimize possible feedback that could otherwise contribute to differences in manual presentation of stimuli and evoked responses. WDR neurons responded with greater frequency to noxious pinch as opposed to non-noxious brush stimulation, demonstrating that they encode stimulus intensity. Purely non-nociceptive neurons were qualitatively identified based upon responses to mechanical stimuli; innocuous brush elicited maximal responding while noxious pinch failed to evoke neuronal activity (Hohmann et al. 1995; Martin et al. 1996) .
Aβ-, Aδ-and C-fiber-mediated responses evoked by transcutaneous electrical stimulation of the peripheral receptive field were characterized using the method of Chapman and Dickenson (1997). Aβ-, Aδ-and early C-fiber-mediated responses occurred and 90-300 ms post-stimulation, respectively. Evoked responses occurring 300-800 ms post-CB 2 modulation of C-fiber responses in WDR neurons 7 stimulation were attributed to C-fiber sensitization (afterdischarge). Spontaneous activity was assessed over 100 ms immediately preceding each electrical stimulation within a given train.
Electrophysiological Recording and Stimulation
Extracellular recordings were obtained from isolated neurons using 3 MΩ tungsten microelectrodes (FHC Inc., Brunswick, ME). One cell was recorded per rat. Two stimulating electrodes were placed transcutaneously within the center of the receptive field of isolated WDR neurons. Neuronal activity was evoked by a train of 16 electrical stimuli (2 ms pulses, 2 s apart) applied every 10 min. Stimuli were delivered at a voltage level near threshold (Strangman and Walker 1999) . Stable baseline responsiveness to electrical stimulation of the receptive field was quantified over a 30 min period prior to drug or vehicle administration.
Responsiveness to successive trains of transcutaneous electrical stimulation was subsequently assessed over 90 min following local administration of carrageenan or saline.
Our previous work demonstrated that the 90 min post-carrageenan time interval was sufficient for observing a CB 2 -mediated suppression of inflammatory nociception (Nackley et al. 2003a,b) . Upon conclusion of recording, rats were sacrificed by intravenous injection of pentobarbitol. Recording depth was documented to the nearest 5 µMs.
Pharmacological Manipulations
After stable baseline responsiveness to electrical stimulation was established, drug or vehicle was administered either systemically (2 ml/kg i.v.) or locally (50 µl i.pl.) in the plantar surface of the hind paw just prior to intraplantar administration of carrageenan or saline. Doses of AM1241 employed here suppressed the development of carrageenan-evoked Fos protein-expression and pain behavior through a CB 2 -specific mechanism (Nackley et al. 2003a ). Doses of SR141716A and SR144528 were chosen based upon their ability to block respectively, following systemic administration. Rats received a unilateral intraplantar injection of carrageenan (3%, 100 µl) or saline together with drug or vehicle.
Experiment 1: Effects of AM1241 on WDR neurons in the absence of carrageenan inflammation. Effects of intravenous administration of AM1241 on activity evoked by transcutaneous electrical stimulation (electrically-evoked activity) in spinal WDR neurons were evaluated. Separate groups of rats received intravenous injections of AM1241 (330 µg/kg; n = 6) or vehicle (n = 6) just prior to intraplantar administration of saline (100 µl).
Saline was administered in the plantar surface of the hind paw to control for the volume of carrageenan injected at the same site in experiment 2. Effects of the intraplantar injection alone on electrically-evoked activity in WDR neurons were evaluated in a separate control group (n = 6). Separate groups of rats received intravenous injections of AM1241 (330 µg/kg; n = 6), vehicle (n = 6), SR144528 (1 mg/kg; n = 5), SR141716A (1 mg/kg; n = 6), SR144528 (1 mg/kg) together with AM1241 (n = 6) or SR141716A (1 mg/kg) together with AM1241 (n = 6) just prior to intraplantar administration of carrageenan.
Experiment 3: Site of action of AM1241. To evaluate the site of action of AM1241 in modulating the activity of spinal WDR neurons, AM1241 (33 or 330 µg/kg i.pl. n = 6 per group) or vehicle (n = 6) was injected concurrently with carrageenan in the plantar surface of the hind paw. Separate groups of rats received AM1241 (33 µg/kg i.pl.; n = 6) in the contralateral (noninflamed) paw. A separate control group received intraplantar saline together with vehicle (n = 6) to verify that changes in electrically-evoked neuronal activity could not be attributed to the injection alone.
Effects of AM1241 on Peripheral Edema. In experiments 2 and 3, paw diameter, defined as the region extending from the mid-plantar surface to the mid-dorsal surface of the paw, was measured in duplicate (to the nearest 0.1 mm) using a caliper square (Honore et al. 1996; Nackley et al. 2003a,b) . Measurements were obtained prior to carrageenan administration and upon termination of the recording period, approximately 2 h subsequent to the induction of inflammation.
Experiment 4: Effects of AM1241 on low threshold neurons. Effects of AM1241 on
electrically-evoked responses elicited in purely non-nociceptive lumbar dorsal horn were assessed by administering AM1241 (330 µg/kg; n = 3) or vehicle (n = 3) intravenously just prior to intraplantar carrageenan.
Data Analysis
Data was acquired using a CED 1401 interface (Cambridge Electronic Design, Cambridge UK) and a Pentium III computer with Spike-2 software. Spike shapes were templated and monitored throughout the recording interval to confirm that action potentials from the original cell of interest were recorded. Electrophysiological data was analyzed by ANOVA for repeated measures and Fisher's PLSD post hoc tests. ANOVA was used to assess the statistical significance of experimental differences in the number of spontaneous and stimulation-evoked action potentials attributed to Aβ-, Aδ-and C-fiber-mediated responses. C-fiber-mediated action potentials were analyzed in terms of early, afterdischarge and total responses. 
General characteristics of sampled neuronal population
Recordings were obtained from 77 wide dynamic range neurons and 6 nonnociceptive neurons. One cell was recorded per animal. WDR neurons were sampled from the lumbar dorsal horn in all experiments, as indicated by depths of recording sites. All cells responded to brush and pinch and encoded stimulus intensity as they responded with greater frequency to noxious pinch relative to nonnoxious brush. Sampled neurons exhibited windup in response to trains of electrical stimuli applied to the cutaneous receptive field. Current used to activate neurons did not differ between groups or between studies and ranged from 2.0-5.5 mA. General characteristics of the sampled neuronal populations are summarized in Table 1 .
Intraplantar administration of saline together with the vehicle for cannabinoid administration failed to reliably alter Aβ-, Aδ-or C-fiber-mediated neuronal responses or windup. By contrast, time-dependent changes in total C-fiber-mediated responses were reliably induced by carrageenan in experiments 2 and 3 (P < 0.02 for all comparisons). Cfiber-mediated afterdischarge, Aβ-and Aδ-fiber-mediated responses did not differ reliably between groups before or after carrageenan administration and did not increase as a function of inflammation (Fig. 5 B,E,F).
Effects of AM1241 on spontaneous activity
Prior to intraplantar administration of carrageenan or saline, levels of spontaneous firing were low and did not differ between groups in any experiment. No differences in spontaneous firing were observed over time or between groups in experiment 1. Intraplantar carrageenan increased spontaneous firing in controls in experiment 2 (F 1,32 = 14.45, P < observed (P = 0.06; Fig. 1A ). In experiment 3, spontaneous activity was lower in groups receiving intraplantar (i.pl.) injections of AM1241 (33 or 330 µg/kg ipsilateral (ipsi) or 33 µg/kg contralateral (contra) to the site of carrageenan administration) relative to vehicle (F 3,20 = 11.46, P < 0.0002; P < 0.002 for all comparisons). Time-dependent changes in spontaneous activity were induced by the experimental treatment in control animals ( 
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Experiment 2: Effects of AM1241 on WDR neurons during the development of carrageenan inflammation
Total C-fiber-mediated activity was lower in groups receiving AM1241 relative to vehicle (F 3,20 = 6.02, P < 0.005; Fig. 3A ). Intravenous administration of AM1241 maximally suppressed total C-fiber-mediated responses relative to controls at 70-90 min following carrageenan administration (F 9,60 = 5.29, P < 0.0003; P < 0.002 for all comparisons). The CB 2 antagonist, SR144528 (P < 0.008) blocked the AM1241-induced suppression of total Cfiber mediated responses, but the CB 1 antagonist SR141716A failed to do so.
AM1241 (330 µg/kg, i.v.) suppressed early C-fiber-mediated activity relative to vehicle (F 3,20 = 3.29, P < 0.05; Fig. 3B ). The suppressive effects of AM1241 (P < 0.007 relative to vehicle) were blocked by the CB 2 antagonist. Early C-fiber-evoked responses observed in rats receiving the CB 2 antagonist together with AM1241 did not differ from vehicle. The suppressive effects of AM1241 on early C-fiber-mediated responses were timedependent (F 9,60 = 3.16, P < 0.008). At 70-90 min post-carrageenan, AM1241 suppressed early C-fiber-mediated activity relative to vehicle (P < 0.02). This suppression was blocked by the CB 2 antagonist SR144528 (P < 0.02) at 70-90 min after inflammation, but not by the CB 1 antagonist SR141716A.
C-fiber-mediated afterdischarge differed between groups receiving AM1241 and control conditions (F 3,20 = 5.56, P < 0.007; Fig. 3C ). The AM1241-induced suppression of Cfiber-mediated afterdischarge was blocked by SR144528 (P < 0.02), but not by SR141716A.
The AM1241-induced suppression of C-fiber-mediated afterdischarge became more pronounced as inflammation developed over time (F 9,60 = 3.90, P < 0.02). Preemptive administration of AM1241 attenuated C-fiber-mediated afterdischarge beginning 10 min
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following the induction of inflammation (P < 0.01 for all comparisons). The suppressive effect of AM1241 on C-fiber-mediated afterdischarge was blocked by SR144528 beginning 40 min post-carrageenan (P < 0.02 for all comparisons).
The percentage of pre-inflammation windup differed in groups receiving AM1241
and vehicle (F 3,20 = 4.52, P < 0.02; Fig. 3D ). AM1241 suppressed windup 10-90 min following the induction of inflammation (F 9,60 = 3.48; P < 0.02 for all comparisons).
Administration of SR141716A failed to block the suppressive effects of AM1241 on windup (P < 0.02 relative to vehicle), while animals receiving SR144528 together with AM1241
showed levels of windup comparable to those receiving vehicle.
Aβ-and Aδ-fiber-mediated responses did not differ reliably between groups before or after carrageenan administration (Fig. 3E,F) . Moreover, no increases in Aβ-fiber-mediated activity were observed as a function of inflammation at 70-90 min post-injection. Effects of SR144528 or SR141716A administration on Aβ-, Aδ-, C-fiber-mediated responses and windup did not differ from vehicle.
The suppressive effects of AM1241 on C-fiber activation and windup were enhanced in the presence of inflammation (Fig. 4) . The suppression of C-fiber-mediated afterdischarge was greater in inflamed rats relative to noninflamed rats 70-90 min post-injection (F 3,30 = 3.75, P < 0.05; Fig. 4C) . A trend towards a greater AM1241-induced attenuation of total Cfiber-mediated activity was observed in rats receiving carrageenan (P < 0.07; Fig. 4A ).
AM1241 also produced a greater suppression of windup 40-90 min following intraplantar administration of carrageenan relative to intraplantar administration of saline (F 3,30 = 4.86, P < 0.03; Fig. 4D ). Time-dependent changes in windup, relative to baseline, were also induced by locally administered AM1241 during the development of inflammation (F 9,60 = 2.36, P < 0.04; Fig.   5D ). A trend towards an AM1241-induced attenuation of the percentage of pre-inflammation windup was observed (P = 0.065). At 70-90 min post-carrageenan, the high dose (330 µg/kg i.pl.) of AM1241 suppressed windup relative to controls (P < 0.005), while the low dose (33 µg/kg i.pl.) failed to do so.
CB 2 modulation of C-fiber responses in WDR neurons
The effects of AM1241 were mediated, at least in part, locally in the paw; AM1241 administered to the ipsilateral (carrageenan-injected) paw suppressed early and total C-fiber-mediated neuronal responses and windup relative to the same dose applied to the contralateral (noninflamed) paw (Fig. 5) . Example records show the effects of AM1241 and vehicle on neuronal responses evoked by transcutaneous electrical stimulation in spinal WDR neurons before and after concurrent administration of carrageenan (Fig. 6) .
Peripheral edema
Prior to administration of carrageenan, paw diameter did not differ between groups paw diameter in the inflamed paw relative to control (F 15,87 = 239, P < 0.03 and F 9,60 = 32.73, P < 0.0001 in experiments 1 and 2, respectively, P < 0.03 for all comparisons) conditions (Fig. 7) . The anti-inflammatory effects of intravenously administered AM1241 were blocked by the CB 2 antagonist SR144528 (P < 0.02) but not the CB 1 antagonist SR141716A (Fig. 7) .
No group differences in paw diameter were observed in the noninflamed contralateral paw before or after carrageenan administration.
Experiment 4: Effects of AM1241 on non-nociceptive neurons during the development of carrageenan inflammation
Non-nociceptive neurons were sampled from the dorsal horn and responded with increased frequency to non-noxious brush relative to noxious pinch (Table 1) . Prior to carrageenan and during the development of inflammation, levels of spontaneous firing were low and did not differ between groups. Current used to activate neurons ranged from 2.8-5.2 mA. Administration of AM1241 (330 µg/kg i.v.) failed to alter Aβ-fiber-mediated responses in these purely non-nociceptive neurons (Fig. 8) In the present work, transcutaneous electrical stimulation of the peripheral receptive field was used to study the effects of the CB 2 -selective cannabinoid agonist AM1241 on the excitability of spinal WDR neurons. Spike shapes were monitored throughout the recording interval and used to confirm that action potentials from the original cells of interest were recorded. Thus, group differences cannot be attributed to changes in the cell population sampled after the induction of inflammation or injection procedures. The state of anesthesia is unlikely to complicate our findings as it failed to obscure detection of anti-inflammatory actions of AM1241 in the present work.
Transcutaneous electrical stimulation directly depolarizes primary afferent axons, which in turn excite WDR neurons in the spinal dorsal horn. Action potentials thus generated bypass normal transduction mechanisms initiated by activation of nerve terminal receptors.
Therefore, transcutaneous electrical stimulation can be used to specifically study central changes in spinal dorsal horn neuronal excitability (Li et al. 1999 ). The present work demonstrates that local or systemic AM1241 administration produces a CB 2 -mediated suppression of C-fiber responses and windup in spinal WDR neurons; this suppression was observed in both the absence and presence of carrageenan inflammation. These findings are in agreement with previous work showing that CB 2 -selective agonists are antinociceptive in models of acute (Malan et al. 2001 ) and chronic pain (Hanus et al. 1999; Clayton et al. 2002; Nackley et al. 2003a; Quartilho et al. 2003; Ibrahim et al. 2003; Hohmann et al. 2004 ).
In the absence of inflammation or prior stimulation, primary afferent C-fibers lack spontaneous, ongoing discharges. However, noxious input can quickly enhance the sensitivity of spinal neurons for further C-fiber inputs. Spinal neuronal excitability may
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increase through several mechanisms including: 1) a cumulative depolarization that lowers the threshold for action potential initiation (induced by increased spontaneous or ongoing activity of primary afferents) (Sivliotti et al. 1993) , 2) presynaptic facilitation (e.g. increased excitatory amino acid or tachkinin release evoked by prior primary afferent activation) (Gerber and Randic 1989; Urban and Randic 1984; Yoshimura and Jessell 1990) , and 3) increased efficacy of postsynaptic receptors induced by prior activation of spinal neurons (e.g.
due to facilitation of signal transduction/second messenger coupling and/or receptor upregulation) (Schmidt 1971; Sorkin and Puig 1996; Sorkin et al. 1998) . In the present study, increased WDR neuronal excitability likely resulted from the summation of depolarizing post synaptic potentials in WDR neurons and/or presynaptic facilitation as these changes can occur within minutes, while an increase in postsynaptic receptor number or efficacy takes much longer.
The effects of AM1241 on WDR neurons in the absence of inflammation
In noninflamed rats, spontaneous activity and C-fiber-mediated responses of WDR neurons were fairly stable across the recording interval, suggesting that there was little ongoing discharge in the primary afferents in the absence inflammation. Nonetheless, AM1241 suppressed C-fiber-mediated responses and windup. This suppression likely involves a CB 2 -mediated attenuation of presynaptic facilitation, rather than a change in ongoing primary afferent discharge. It is possible that repeated electrical stimulation, cutaneous pinch application and/or intraplantar injection itself induced local inflammatory processes in the absence of carrageenan that led to increased neurotransmitter release by the same number of action potentials. This explanation requires that low levels of receptive field stimulation are sufficient to induce rapid, long term changes via the above mechanisms.
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However, the relatively short time course for the observed changes likely precludes a role for modifications in postsynaptic receptor number or efficacy.
The effects of AM1241 on WDR neurons in the presence of inflammation
Peripheral carrageenan produces local C-fiber sensitization and subsequent spinal WDR neuronal hyperexcitability (Woolf et al. 1994; Hedo et al. 1998 ). In the presence of carrageenan inflammation, increases in WDR neuronal activity may involve increased ongoing discharge as well as presynaptic facilitation. This dual mechanism may account for the increase in spontaneous activity, C-fiber responsiveness, and windup observed during the development of inflammation as well as the more pronounced suppressive effect of AM1241
in the presence vs. the absence of inflammation. These observations suggest a preferential effect of peripheral CB 2 activation in suppressing inflammation-evoked sensitization of Cfiber-mediated responses of WDR neurons (Svendsen et al., 1999; Zhang et al., 2001) .
Peripheral edema
AM1241 also produced a CB 2 -mediated anti-inflammatory effect, consistent with previous findings (Nackley et al. 2003a; Quartilho et al. 2003) . Systemic or local administration of AM1241 likely prevented the release of inflammatory mediators, thereby reducing inflammation-evoked ongoing discharge and presynaptic facilitation, mechanisms contributing to the enhanced spinal neuronal excitability we observed during the development of inflammation.
Effects of AM1241 on non-nociceptive neurons during the development of inflammation
AM1241 does not act as a local anesthetic. Local anesthetics typically reduce neuronal responses by blocking Na + channels, resulting in a suppression of electricallyevoked Aβ activity in non-nociceptive cells as well as C-fiber-mediated activity in WDR neurons (Chapman et al. 1997 ). In our study, low threshold, purely nonnociceptive spinal neurons did not show sensitization during the development of inflammation and were not altered by AM1241 actions in the periphery. By contrast, high threshold neurons in the spinal dorsal horn do relay nociceptive information to supraspinal sites and undergo sensitization (Woolf et al. 1994) . Future studies should assess the effects of CB 2 activation on high threshold cells to fully elucidate the consequences of CB 2 activation on nociceptive transmission.
Possible mechanisms of action of AM1241
Our findings are consistent with the possibility that AM1241 produces analgesia by suppressing peripheral nociceptor sensitization that may lead to central sensitization.
However, the mechanism by which AM1241 suppresses WDR neuronal responses enhanced by ongoing primary afferent discharges and presynaptic facilitation remains to be determined. AM1241 may also indirectly suppress primary afferent activation by stimulating local release of β-endorphin in peripheral tissue; AM1241 stimulates β-endorphin release in both rat hindpaw skin and cultured keratinocytes (Malan et al., 2004) . Furthermore, antinociception induced by AM1241 is blocked by either naloxone or antiserum to β-endorphin and is absent in both µ-opioid and CB 2 receptor knockout mice (Malan et al., 2004) . CB 2 mRNA expression is also induced in the lumbar spinal cord coincident with the appearance of activated microglia (Zhang et al., 2003) , suggesting that additional targets for CB 2 agonists may also be present in pathological pain states. It is therefore plausible that AM1241 produces antinociception via a combination of the aforementioned mechanisms.
Conclusion
CB 2 agonists offer considerable potential as a novel pharmacotherapy for pain as they fail to produce centrally-mediated effects commonly associated with CB 1 (Hanus et al. 1999; Malan et al. 2001; Patel et al. 2003) . Furthermore, such compounds are unlikely to be psychoactive or addictive. The present work provides evidence that activation of a peripheral CB 2 m echanism is sufficient to suppress C-fiber-evoked responses and windup at the level of the spinal dorsal horn. This suppression was observed in WDR neurons, which are known to modulate nociception and contribute to the ascending pain pathway, the spinothalamic tract.
These data collectively suggest that CB 2 agonists may be employed preemptively to attenuate the development of persistent pain in the absence of unwanted central side-effects. (1 cell/rat). 
